FDA report highlights need to improve diversity in clinical trials
There has been a real push among the industry to improve diversity in trials. The FDA report shows diversity statistics from US trials.
There has been a real push among the industry to improve diversity in trials. The FDA report shows diversity statistics from US trials.
PhaseV will analyse NeuroSense’s Phase II ALS trial data, and results from these will inform Phase III trial design, enrolment, and cost-effectiveness.
The pharmaceutical industry continues to be a hotbed of patent innovation. Activity is driven by the evolution of new treatment...
MMI pioneers Symani Surgical System in first US cases
“Defensibility” key for AI-centric small biotechs seeking investment
Klineo wins €2m to advance AI patient recruitment platform
Hyperfine starts enrolment in portable imaging workflow study